ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder (ADEPT)
ADEPT: Augmenting DBT Effectiveness With Psilocybin-Assisted Therapy
ADEPT is an open-label proof-of-concept study evaluating the safety and tolerability of psilocybin-assisted therapy in conjunction with Dialectical Behavior Therapy for participants with borderline personality disorder.
Participants enrolled in the M Health Fairview Dialectical Behavior Therapy program will receive preparation therapy sessions, two supervised 25 mg psilocybin dosing sessions, integration therapy sessions, and a final follow-up visit. Participants will continue their usual DBT program during study participation.
The study will primarily assess safety and tolerability, including adverse events, treatment-emergent adverse events, serious adverse events, suicidal ideation, challenging psychedelic experiences, psilocybin-related side effects, study retention, therapy session attendance, and assessment completion.
調査の概要
状態
詳細な説明
ADEPT is an open-label proof-of-concept study designed to assess the safety and tolerability of combining psilocybin-assisted therapy with Dialectical Behavior Therapy in participants with borderline personality disorder.
The study will enroll up to 18 participants who have a confirmed DSM-5 diagnosis of borderline personality disorder and are enrolled in the M Health Fairview Dialectical Behavior Therapy program. Participants must have been enrolled in DBT for at least one month and must have consistent attendance in both group and individual therapy.
The study intervention includes two 25 mg doses of psilocybin administered during supervised dosing visits. Three preparation therapy visits will occur before the first dosing visit. The first dosing visit will be followed by three integration therapy visits. A second psilocybin dosing visit will occur approximately 21 days later, followed by three additional integration therapy visits. Participants will complete a final follow-up visit at week 18, approximately 12 weeks after the second dosing visit.
Participants will continue their usual DBT program while enrolled in the study. The M Health Fairview DBT program includes weekly individual therapy, group therapy skills development, and access to phone coaching.
The primary focus of the study is safety and tolerability. Participants will be monitored during and after dosing, and adverse events, treatment-emergent adverse events, serious adverse events, suicidal ideation, challenging experiences, and psychedelic-related side effects will be assessed. Secondary outcomes will evaluate changes in borderline personality disorder symptoms, emotion regulation, depressive symptoms, quality of life, treatment credibility and expectancy, mystical experience, and continued participation in DBT after psilocybin-assisted therapy.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前：Ziad Nahas, MD, MSCR
- 電話番号：952-525-4505
- メール：znahas@umn.edu
研究連絡先のバックアップ
- 名前：Rachel Johnson, MA, PhD
- 電話番号：952-525-4505
- メール：ipl@umn.edu
研究場所
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455
- M Health Fairview DBT Program
-
コンタクト：
- Ziad Nahas, MD, MSCR
- 電話番号：952-525-4505
- メール：ipl@umn.edu
-
Saint Louis Park、Minnesota、アメリカ、55416
- M Physicians St. Louis Park Clinic
-
コンタクト：
- Ziad Nahas, MD, MSCR
- 電話番号：952-525-4505
- メール：ipl@umn.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Confirmed DSM-5 diagnosis of borderline personality disorder using clinical records and measures used in the M Health Fairview DBT program
- Enrolled in the M Health Fairview DBT program for at least one month, with consistent attendance in group and individual therapy
- Age 25 to 65 years
- Able to speak and understand English
- Ability to complete all protocol-required assessment tools without assistance or alteration to copyrighted assessments
- Ability to comply with all study visits
- Stated willingness to comply with all study procedures and avoid changes to current treatments for the duration of the study
- If of childbearing potential, use of an acceptable birth control method, including abstinence
Exclusion Criteria:
- Refusal to give informed consent
- History of bipolar affective disorder type I or II, schizophrenia, psychosis, delusions, paranoia, schizoaffective disorder, or substance use disorder within the past 12 months
- First- or second-degree relative with schizophrenia or any other psychotic disorder
- Active suicidal ideation with at least some intent and/or plan, defined as a current score of 4 or 5 on the C-SSRS
- History of suicide attempt in the last 6 months
- Comorbid autism
- Pregnant or may have reason to believe they are pregnant
- Pre-existing valvular heart disease or pulmonary hypertension
- Active primary PTSD diagnosis
- Psychiatric or other condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin
- Any medical or psychiatric disorder, disease, condition, injury, symptom, or circumstance that may reduce ability to fulfill study requirements, adversely impact data integrity or validity, or pose increased risk during study participation
- Children
- Prisoners
- Adults lacking capacity to consent or adults with diminished or fluctuating capacity to consent
- Non-English speakers
- Individuals unable to read
- Employees of the researcher
- Students of the researcher
- Active members of the military or DoD personnel
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：DBT Plus Psilocybin-Assisted Therapy
Participants enrolled in the M Health Fairview Dialectical Behavior Therapy program will receive psilocybin-assisted therapy in addition to ongoing DBT. The study includes three preparation visits, two psilocybin dosing visits, integration visits after each dosing visit, and a final follow-up visit at week 18. |
Participants will receive two 25 mg doses of psilocybin during supervised dosing visits. Each dosing visit will include study therapist support for a minimum of 6 hours, with preparation and integration therapy sessions before and after dosing.
他の名前：
Participants will continue in the M Health Fairview Dialectical Behavior Therapy program while receiving psilocybin-assisted therapy. The study therapy sequence includes three preparation visits before the first dosing session, three integration visits after the first dosing session, a second dosing session, and three additional integration visits.
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence, Severity, and Frequency of Adverse Events
時間枠：Baseline through final study visit at week 18
|
Safety and tolerability will be assessed by the incidence, severity, and frequency of adverse events, treatment-emergent adverse events, and serious adverse events during the study. |
Baseline through final study visit at week 18
|
|
Acute Suicidal Ideation After Psilocybin Dosing
時間枠：Within 24 hours after each dosing visit
|
Acute suicidal ideation will be assessed after each psilocybin dosing visit using the Modified Scale for Suicidal Ideation and related safety assessments. |
Within 24 hours after each dosing visit
|
|
Challenging Experiences After Psilocybin Dosing
時間枠：Integration visit 24 hours after each dosing visit
|
Challenging experiences after psilocybin dosing will be assessed using the Challenging Experiences Questionnaire. |
Integration visit 24 hours after each dosing visit
|
|
Psilocybin-Related Side Effects
時間枠：Integration visit 24 hours after each dosing visit
|
Psilocybin-related side effects will be assessed using the Swiss Psychedelic Side Effects Inventory. |
Integration visit 24 hours after each dosing visit
|
|
Percentage of Participants Who Complete the Study
時間枠：Baseline through final study visit at week 18
|
Study retention will be assessed as the percentage of enrolled participants who complete the final study visit at week 18. Unit: percentage of participants |
Baseline through final study visit at week 18
|
|
Percentage of DBT Therapy Sessions Attended
時間枠：Baseline through final study visit at week 18
|
Dialectical Behavior Therapy session attendance will be assessed as the percentage of scheduled DBT therapy sessions attended during study participation. Unit: Percentage of sessions |
Baseline through final study visit at week 18
|
|
Percentage of Study Assessments Completed
時間枠：Baseline through final study visit at week 18
|
Assessment completion will be assessed as the percentage of scheduled study assessments completed during study participation. Unit: percentage of assessments |
Baseline through final study visit at week 18
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Zanarini Rating Scale Score
時間枠：Baseline to final study visit at week 18
|
Borderline personality disorder symptoms will be assessed using the Zanarini Rating Scale. Change in score will be assessed from baseline to the final study visit at week 18. Higher scores indicate greater borderline personality disorder symptom severity. Unit: Points |
Baseline to final study visit at week 18
|
|
Change in Personality Inventory for DSM-5 Score
時間枠：Baseline to final study visit at week 18
|
Borderline personality disorder symptoms will be assessed using the Zanarini Rating Scale, Personality Inventory for DSM-5, Inventory of Personality Organization, and Difficulties in Emotion Regulation Scale-16. |
Baseline to final study visit at week 18
|
|
Change in Difficulties in Emotion Regulation Scale-16 Score
時間枠：Baseline to final study visit at week 18
|
Emotion regulation difficulties will be assessed using the Difficulties in Emotion Regulation Scale-16. Change in score will be assessed from baseline to the final study visit at week 18. Higher scores indicate greater emotion regulation difficulties. Unit: Points |
Baseline to final study visit at week 18
|
|
Change in Inventory of Personality Organization Score
時間枠：Baseline to final study visit at week 18
|
Personality organization will be assessed using the Inventory of Personality Organization. Change in score will be assessed from baseline to the final study visit at week 18. Higher scores indicate greater impairment in personality organization. Unit: Points |
Baseline to final study visit at week 18
|
|
Change in Montgomery-Asberg Depression Rating Scale Score
時間枠：Baseline, week 8 after the second dose, and 3 months after the last drug dose or at DBT exit
|
Depressive symptoms will be assessed using the Montgomery-Asberg Depression Rating Scale and Quick Inventory of Depressive Symptomatology. Unit: Points |
Baseline, week 8 after the second dose, and 3 months after the last drug dose or at DBT exit
|
|
Change in Quick Inventory of Depressive Symptomatology Score
時間枠：Baseline, week 8 after the second dose, and 3 months after the last drug dose or at DBT exit
|
Depressive symptoms will be assessed using the Quick Inventory of Depressive Symptomatology. Change in score will be assessed from baseline to week 8 after the second dose and 3 months after the last drug dose or at DBT exit. Higher scores indicate greater depressive symptom severity. Unit: Points |
Baseline, week 8 after the second dose, and 3 months after the last drug dose or at DBT exit
|
|
Change in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form Score
時間枠：Baseline to final study visit at week 18
|
Quality of life will be assessed using the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form. Change in score will be assessed from baseline to the final study visit at week 18. Higher scores indicate greater quality of life enjoyment and satisfaction. Unit: points |
Baseline to final study visit at week 18
|
|
Credibility and Expectancy Questionnaire Credibility Score
時間枠：Day before first dosing and day before second dosing
|
Treatment credibility will be assessed using the Credibility and Expectancy Questionnaire. Scores will be assessed the day before the first dosing visit and the day before the second dosing visit. Higher scores indicate greater treatment credibility. Unit: Points |
Day before first dosing and day before second dosing
|
|
Credibility and Expectancy Questionnaire Expectancy Score
時間枠：Day before first dosing and day before second dosing
|
Treatment expectancy will be assessed using the Credibility and Expectancy Questionnaire. Scores will be assessed the day before the first dosing visit and the day before the second dosing visit. Higher scores indicate greater treatment expectancy. Unit: Points |
Day before first dosing and day before second dosing
|
|
Mystical Experience After Psilocybin Dosing
時間枠：Integration visit immediately after each dosing visit
|
Mystical experience after psilocybin dosing will be assessed using the Mystical Experience Questionnaire. Higher scores indicate greater intensity of mystical-type experience. Unit: Points |
Integration visit immediately after each dosing visit
|
|
Rate of Continued Participation in Dialectical Behavior Therapy
時間枠：Through final study visit at week 18
|
Continued participation in Dialectical Behavior Therapy after psilocybin-assisted therapy will be assessed as the rate of DBT participation through the final study visit at week 18. Unit: percentage of scheduled DBT sessions attended |
Through final study visit at week 18
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Ziad Nahas, MD, MSCR、University of Minnesota
- スタディディレクター：Devin H Hanson, PhD, LP、University of Minnesota
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- PSYCH-2026-35016
- STUDY00029130 (その他の識別子：University Of Minnesota- IRB)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。